Cargando…

Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time

BACKGROUND: Tuberculosis (TB) is an infectious disease. During TB, regulatory T cells (Treg) are related to poor prognosis. However, information about conventional and unconventional Treg (cTreg and uTreg, respectively) is limited. The tumour necrosis factor (TNF) and its receptors (TNFR1 and TNFR2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Téllez-Navarrete, Norma A., Ramon-Luing, Lucero A., Muñoz-Torrico, Marcela, Preciado-García, Mario, Medina-Quero, Karen, Hernandez-Pando, Rogelio, Chavez-Galan, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278684/
https://www.ncbi.nlm.nih.gov/pubmed/34261449
http://dx.doi.org/10.1186/s10020-021-00320-4
_version_ 1783722310602063872
author Téllez-Navarrete, Norma A.
Ramon-Luing, Lucero A.
Muñoz-Torrico, Marcela
Preciado-García, Mario
Medina-Quero, Karen
Hernandez-Pando, Rogelio
Chavez-Galan, Leslie
author_facet Téllez-Navarrete, Norma A.
Ramon-Luing, Lucero A.
Muñoz-Torrico, Marcela
Preciado-García, Mario
Medina-Quero, Karen
Hernandez-Pando, Rogelio
Chavez-Galan, Leslie
author_sort Téllez-Navarrete, Norma A.
collection PubMed
description BACKGROUND: Tuberculosis (TB) is an infectious disease. During TB, regulatory T cells (Treg) are related to poor prognosis. However, information about conventional and unconventional Treg (cTreg and uTreg, respectively) is limited. The tumour necrosis factor (TNF) and its receptors (TNFR1 and TNFR2) are necessary for mycobacterial infection, and TNFR2 signalling is required to maintain Treg. METHODS: A blood sample of drug-susceptible (DS-TB) and drug-resistant tuberculosis (DR-TB) patients was obtained before (basal) and after 2 and 6 months of anti-TB therapy. Expression of TNF, TNFR1, and TNFR2 (transmembrane form, tm) on cTreg, uTreg, activated CD4+ (actCD4+), and CD4+ CD25− (CD4+) T cell subpopulations were evaluated. The main objective was to identify immunological changes associated with sensitive/resistant Mtb strains and with the use of anti-TB therapy. RESULTS: We found that after 6 months of anti-TB therapy, both DS- and DR-TB patients have decreased the frequency of cTreg tmTNF+, CD4+ tmTNFR1+ and CD4+ tmTNFR2+. Nevertheless, after 6 months of therapy, only DR-TB patients decreased the frequency of actCD4+ tmTNF+ and actCD4+ tmTNFR2+, exhibited a systemic inflammatory status (high levels of TNF, IFN-γ and IL-12), and their purified CD4+ T cells showed that TNF and TNFR2 are up-regulated at the transcriptional level. Moreover, DS- and DR-TB down-regulated TNFR1 and other proteins associated with Treg (FOXP3 and TGFβ1) in response to the anti-TB therapy. CONCLUSION: These results partially explain the differences in the immune response of DS-TB vs DR-TB. The frequency of actCD4+ tmTNFR2+ cells and inflammatory status should be considered in the follow-up of therapy in DR-TB patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-021-00320-4.
format Online
Article
Text
id pubmed-8278684
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82786842021-07-14 Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time Téllez-Navarrete, Norma A. Ramon-Luing, Lucero A. Muñoz-Torrico, Marcela Preciado-García, Mario Medina-Quero, Karen Hernandez-Pando, Rogelio Chavez-Galan, Leslie Mol Med Research Article BACKGROUND: Tuberculosis (TB) is an infectious disease. During TB, regulatory T cells (Treg) are related to poor prognosis. However, information about conventional and unconventional Treg (cTreg and uTreg, respectively) is limited. The tumour necrosis factor (TNF) and its receptors (TNFR1 and TNFR2) are necessary for mycobacterial infection, and TNFR2 signalling is required to maintain Treg. METHODS: A blood sample of drug-susceptible (DS-TB) and drug-resistant tuberculosis (DR-TB) patients was obtained before (basal) and after 2 and 6 months of anti-TB therapy. Expression of TNF, TNFR1, and TNFR2 (transmembrane form, tm) on cTreg, uTreg, activated CD4+ (actCD4+), and CD4+ CD25− (CD4+) T cell subpopulations were evaluated. The main objective was to identify immunological changes associated with sensitive/resistant Mtb strains and with the use of anti-TB therapy. RESULTS: We found that after 6 months of anti-TB therapy, both DS- and DR-TB patients have decreased the frequency of cTreg tmTNF+, CD4+ tmTNFR1+ and CD4+ tmTNFR2+. Nevertheless, after 6 months of therapy, only DR-TB patients decreased the frequency of actCD4+ tmTNF+ and actCD4+ tmTNFR2+, exhibited a systemic inflammatory status (high levels of TNF, IFN-γ and IL-12), and their purified CD4+ T cells showed that TNF and TNFR2 are up-regulated at the transcriptional level. Moreover, DS- and DR-TB down-regulated TNFR1 and other proteins associated with Treg (FOXP3 and TGFβ1) in response to the anti-TB therapy. CONCLUSION: These results partially explain the differences in the immune response of DS-TB vs DR-TB. The frequency of actCD4+ tmTNFR2+ cells and inflammatory status should be considered in the follow-up of therapy in DR-TB patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-021-00320-4. BioMed Central 2021-07-14 /pmc/articles/PMC8278684/ /pubmed/34261449 http://dx.doi.org/10.1186/s10020-021-00320-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Téllez-Navarrete, Norma A.
Ramon-Luing, Lucero A.
Muñoz-Torrico, Marcela
Preciado-García, Mario
Medina-Quero, Karen
Hernandez-Pando, Rogelio
Chavez-Galan, Leslie
Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
title Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
title_full Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
title_fullStr Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
title_full_unstemmed Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
title_short Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
title_sort anti-tuberculosis chemotherapy alters tnfr2 expression on cd4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278684/
https://www.ncbi.nlm.nih.gov/pubmed/34261449
http://dx.doi.org/10.1186/s10020-021-00320-4
work_keys_str_mv AT telleznavarretenormaa antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime
AT ramonluingluceroa antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime
AT munoztorricomarcela antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime
AT preciadogarciamario antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime
AT medinaquerokaren antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime
AT hernandezpandorogelio antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime
AT chavezgalanleslie antituberculosischemotherapyalterstnfr2expressiononcd4lymphocytesinbothdrugsensitiveandresistanttuberculosishoweveronlydrugresistanttuberculosismaintainsaproinflammatoryprofileafteralongtime